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Abstract
Background: T-cell Acute Lymphoblastic Leukemia (ALL) represents about 10–15 % of pediatric ALL cases. EZH2,
one of the components of Polycomb group proteins (PRC2) complex, catalyzes the trimethylation of histone H3
lysine 27 that is associated with transcriptional repression and tumor development.
Methods: We examined the expression levels of PRC2 complex in primary samples of T cells ALL at diagnosis by
western blotting and real time PCR. We evaluated the effect of 3-deazaneplanocin-A (DZNep), an EZH2 inhibitor,
alone and in combination with Daunoblastine on cell viability, apoptotic death and cell cycle distribution of T cell
established Jurkat cell line.
Results: EZH2 was expressed in 75 % samples at different extents mainly with high expression level. SUZ12 was
expressed in 60 % samples and EED in all samples, respectively. The Kaplan-Meier analysis shows that T-ALL
expressing EZH2 had a lower probability of disease-free survival (DFS) compared to T-ALL negative for EZH2 (23 %
vs 100 %) (p = 0.01). The EZH2 inhibitor DZNep used in combination with Daunoblastine was synergistic in inducing
growth inhibition and increasing the apoptosis in T-ALL Jurkat cells at 48 and 72 h paralleled by EZH2 decreased
expression. Moreover, the combination decreased the activity of Erk-1/2 proliferation enzymes with no effects on
Akt survival pathway.
Conclusions: The evaluation of EZH2 expression in pediatric T-ALL can be useful in predict the clinical outcome of the
patients and EZH2 can be a useful target to improve the efficacy of conventional chemotherapy in this subset of patients
with bad prognosis.
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Background
Epigenetic alterations have an important role in
leukemogenesis and Polycomb group proteins, which
consist of two complexes (PRC1 and PRC2), represent a
major class of epigenetic regulators in development and
transcriptional repression. The polycomb repressive
complexes (PRC) are key mediators of transcriptional re-
pression and consists of three core subunits: EED
(embryonic ectoderm development), SUZ12 (suppres-
sor of zeste 12 homolog) and EZH2 (enhancer of zeste
homolog 2). PRC2 controls the pivotal methylation of
lysine 27 of histone H3 (H3K27) catalyzed by the SET-
domain containing enhancer of zest homolog 2
(EZH2) protein and its cofactors [1]. Deregulation of
this histone modification can lead to epigenetic silen-
cing of genes that promote differentiation and leads to
leukemogenesis [2]. Components of PRC2 are required
for embryonic development and notably loss of EZH2
gene is associated with a block in B- and T-cell differ-
entiation. Moreover, EZH2 acts as an oncogene, as it
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is overexpressed in many solid cancers and lymph-
omas, in both advanced and metastatic diseases [3].
EZH2 is one of several chromatin regulatory proteins
that have prompted great clinical and scientific interest
as they offer the possibility of new therapeutic targets in
cancer [4]. EZH2 contributes to cell fate decisions, or-
chestrating gene expression to control the balance
between self-renewal and differentiation and has a pre-
dominant role in embryonic development becoming
down regulated in some adult differentiated tissues [5].
T-cell acute lymphoblastic leukemia (T-ALL) repre-
sents about 10–15 % of pediatric ALL cases and is gen-
erally associated with unfavorable clinical features and
aggressive biologic behavior such as higher risk for
primary resistant disease, early relapse and isolated
central nervous system (CNS) relapse compared to
B-progenitor ALL patients. The prognosis of T-ALL in
children and adolescents has improved in recent years
as a result of more intensive chemotherapy approaches
but it remains worse compared to B-lineage ALL espe-
cially in presence of poor initial response to prednis-
one therapy [5].
Recent articles showed that EZH2 knockdown results in
a significant decrease in cellular proliferation and invasive-
ness, suggesting that epigenetic therapy targeting PcG ma-
chinery to treat various tumors, and the development of
drugs inhibiting the trimethylation of the lysine 27 on his-
tone 3 (H3K27me3) can be effective therapy [6]. H3K27
methylation is catalyzed by the SET domain of EZH2 and
is helped by 2 additional proteins, embryonic ectoderm
development (EED) and suppressor of zeste 12 (SUZ12).
These proteins, together with the histone binding proteins
retinoblastoma binding protein 4 (RBBP4) and RBBP7,
form the core components of PRC2 [7]. Other proteins
such as PHD finger protein 1 (PHF1), which specifically
stimulates H3K27 trimethylation rather than dimethyla-
tion sirtuin 1 (SIRT1), and jumonji, AT rich interactive
domain 2 (Jarid2) are also found in PRC2 complexes likely
acting as modulators [8].
3-deazaneplanocin-A (DZNep) is an interesting agent
that blocks EZH2. DZNep is a promising tool for cancer
therapy. It induces apoptosis of cancer cells but not of their
normal counterparts: epithelial cells and fibroblasts [9] or
more importantly hematopoietic cells [10]. The action of
DZNep is due to its inhibition of S-adenosylhomocysteine
hydrolase, which disrupts methionine metabolism and re-
sults in methyltrasferases inhibition [3]. Similarly to EZH2
knockdown, DZNep reverts epithelial-to-mesenchymal
transition (EMT), and prevents tumor progression, making
it a highly promising anti-tumour agent [6]. A key feature
of epigenetic alterations in malignancy is their relative plas-
ticity, unlike genetic mutations to DNA sequence that are
definitive [4]. Hereafter, there have been increasing num-
bers of reports showing the impressive anticancer effects of
DZNep as a new epigenetic compound in a variety of can-
cer models both in vitro and in vivo [11–16]. The mecha-
nisms and effects of DZNep have been studied in several
solid tumors and acute myeloid leukemia, less is known
about the potential of this compound for T-cell ALL [8].
Daunoblastine, a nonselective class I anthracycline,
acts by binding to DNA-associated enzymes and interca-
lates the base pairs of the DNA’s double helix. Although
daunoblastine has been used as an anti-leukemic agent
for decades, its success is often dependent on combin-
ation with other drugs [17].
In the present study, we examined the expression
levels of EZH2, EED and SUZ12 in samples of T cells
ALL. Moreover, we evaluated the effects of DZNep alone
or in combination with Daunoblastine on established T
cell Jurkat line.
Methods
Lymphoblastic leukemia cells were collected from
pediatric patients diagnosed and treated for T-cell Acute
Lymphoblastic Leukemia (T-ALL) at the Pediatric Oncol-
ogy Unit of Second University of Naples and isolated from
bone marrow at diagnosis with density gradient centrifu-
gation Histopaque-1077 (1.077 g/ml; Sigma-Aldrich).
The study was approved by the Ethical Committee of the
Azienda Universitaria Policlinico of the Second University
of Naples (n. 94 on 21 January 2014) in compliance with
the Helsinki Declaration. The informed consent for the
participation to the study was approved and signed by the
parents of the children.
Protein extraction and western blot analysis
Protein extraction was performed on ice for 30 min
using lyses-buffer with protease-inhibitors. Total protein
concentration was determined using Bradford assay
(Bio-Rad). 30 μg of total protein was run on 10 % polya-
crylammide gel and blotted onto PVDF membrane
(Millipore, Marlborough, MA). Immunoblotting was
performed using primary antibodies against EZH2 (C-1),
EED (H-300), SUZ12 (D-10) Bcl2 (C-2) (Santacruz Bio-
technology, INC). Primary antibodies AKT, pAKT, ERK,
pERK were obtained from Cell Signaling. All secondary
antibodies were obtained from Santa Cruz Biotecnology.
All antibodies were used in accordance with manifac-
turer’s instructions. Bands were visualized using a
chemiluminescent system (ECL-Amersham). The inten-
sity of each band was determined using a CCD camera
and Quantity One 1-D analysis software (Biorad Labora-
tories). Results were normalized against the level of β-
tubulin (Santa Cruz Biotechnologies) expression in each
sample. It was obtained a range of expression of the
bands from 0 to 175 %, with a median value of 60 %.
Therefore, we have selected intensity values higher than
60 % in order to consider the expression of the different
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proteins as high. Values of the intensities associated to
the specific bands of the different proteins lower or
equal to 60 % were considered as low expression.
RNA extraction and quantitative real-time PCR
Total RNA was extracted from cell cultures using
TRI REAGENT (Molecular Research Center Inc., OH,
USA) according to the manufacturer’s protocol. RNA
from bone marrow at diagnosis was extracted with
RNeasy FFPE kit (Invitrogen). The reactions were run
on an ABI PRISM®7900HT Sequence Detection Sys-
tem; the cycling conditions were 10 min at 95 °C
followed by 40 cycles of 15 s at 94 °C and 1 min at
68 °C. In the first step, we determined the stability of
a control gene (β-actin) for the normalization of the
real-time PCR products. Specific primers for human
EZH2, SUZ12 and EED were designed (Table 1). As-
says were performed in triplicate. We used the 2-ΔΔCt
method to analyze the data obtained.
Cell culture
Human T cell leukemia, Jurkat cell lines, obtained from
the German Collection of Microorganisms and Cell Cul-
tures (DMSZ) were grown in RPMI media supplemented
with heat inactivated 10 % FBS and 1 % Penicillin/
Streptomycin in a humidified atmosphere of 95 % air/
5 % CO2 at 37 °C.
Chemical reagents
DZNep was purchased from Sigma-Aldrich, dissolved in
distilled water and stored as frozen aliquots at −20 °C.
Daunoblastine was obtained from Pfizer Pharma and di-
luted in physiological saline solution.
Cell viability assay
Cell viability was analyzed by MTT [3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide]
assay. Cells were seeded in 96-well plates at the density of 1
× 103 cells/well in a final volume of 100 μL and then incu-
bated at 37 °C in a humidified atmosphere. Cells were
treated with DZNep at a range of concentrations between
0.15 and 24 μM/ml and with Daunoblastine at a range of
concentrations between 2.5 to 150 ng/ml, in either single or
combined treatments. Cells were exposed to a solution of
10 % MTT to 48 h and 72 h from the treatments, for 4 h at
37 °C to form formazan crystals by reacting with metabolic-
ally active cells. The formazan crystals were solubilized in a
1 N isopropanol/HCL 10 % solution at 37 °C for 30 min.
The absorbance was determined at 595 nm [18]. Cell viabil-
ity was determined by the formula: Cell viability (%) ‐ (ab-
sorbance of the treated wells ‐ absorbance of the blank
control wells)/(absorbance of the negative control wells ‐
absorbance of the blank control wells) × 100 %. We have
calculated 50 % growth inhibition index (IC 50) for DZNep
and Daunoblastine.
Drug combination studies
This study allowed the evaluation of the synergistic in-
hibition of cell growth produced by DZNep and Dauno-
blastine alone and in combination in Jurkat. Cells were
seeded in 12-multi-weel plates at the density of 1 × 106
cells/ml medium. After 24 h at 37 °C with 5 % CO2 in a
humidified atmosphere, the cells were treated at the
drugs range of concentrations described above. Drug
combination studies were based on concentration-effect
curves generated as a plot of the fraction of unaffected
(surviving) cells versus drug concentration after 48 h of
treatment. To explore the relative contribute of each
agent to the synergism, the combination index (CI) for
DZNep and Daunoblastine was obtained with software
CalcuSyn. A CI of less than, equal to, and more than 1
indicates synergy, additivity, and antagonism, respect-
ively as previously described [19].
Cell cycle analysis
Jurkat cell line were seeded at the density of 1 x 106 and
treated with DZNep and Daunoblastine in humidified at-
mosphere at 37 °C for 48 h. After incubation, cells were
washed in PBS, resuspended and directly stained in a
Propidium Iodide (PI) solution for 30 min at 4 °C in the
dark. Flow cytometry analysis was performed using
FACScan (Becton Dickinson, San Jose, CA). To evaluate
cell cycle, PI fluorescence was collected as FL2 (linear
scale) by the ModFIT software (Becton Dickinson). For
the evaluation of intracellular DNA content, at least
20,000 events for each point were analyzed in at least
three different experiments giving a S.D. less than 5 %.
Evaluation of apoptosis by DNA-flow cytometry
Apoptotis was analyzed by Annexin-V kit (MedSystems
Diagnostics, Vienna, Austria). During the early stages of
apoptosis, phosphatidylserine residues translocated from
the inner to the outer leaflet of the plasma membrane bind-
ing Annexin-V-FITC. Jurkat cell line was treated with
DZNep and/or Daunoblastine, for 48 h. After treatment,
cells were collected and incubated with Annexin-V-FITC
in a binding buffer (provided by the manufacturer) for
30 min at 4 °C. Analysis of apoptotic cells was performed
by flow cytometry (FACS Aria III, Becton Dickinson). For
Table 1 Primer sequences for quantitative real time-polymerase
chain reaction
Gene Sense Antisense
EZH2 5′cgcttttctgtaggcgatgt 3′ 5′tgggtgttgcatgaaaagaa 3′
SUZ12 5′gggagactattcttgatgggaag 3′ 5′actgcaacgtaggtccctga 3′
EED 5′gaaattccatccaagagatcca 3′ 5′tggatattccataatcgtaaagca3′
β-actin 5′gcgagaagatgacccagatc 3′ 5′ggatagcacagcctggatag 3′
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each sample, 10x104 events were acquired. Analysis was
carried out by triplicate determination on at least three dif-
ferent experiments.
AKT kinase assay
Cells were cultured and treated with DZNep and/or
Daunoblastine and lysed as previously described [20].
Then, 20 μl of IgG1 anti-Akt monoclonal antibody agar-
ose beads immobilized (Cell Signaling Technology) was
added to 1 mg of cell lysate and the mixture was incu-
bated at 4 °C for the night in gentle agitation. The result-
ing immunoprecipitates were then incubated for 30 min at
30 °C with 1 mg GSK-3 fusion protein (Cell Signaling Tech-
nology) in the presence of 200 mM ATP and Kinase Buffer
(25 mM Tris, pH 7.5, 5 mM b-glycerophosphate, 2 mM
dithiotreitol, 0.1 mM sodium orthovanadate, 10 mM
MgCl2). The reaction was terminated with the addition of
20 μl 2 × SDS sample buffer. The supernatants were boiled
for 5 min and electrophoresed by 12 % SDS‐PAGE and
the protein electro-transferred on a nitrocellulose film.
Phosphorylation of GSK-3 was detected using as probe an
anti-Phospho-GSK-3a/b (Ser21/9) rabbit polyclonal anti-
body (diluted 1:1000) and then with a secondary anti-
rabbit HRP-conjugated monoclonal antibody, (diluted
1:2000). The film was washed with TBS 13–0.05 % Tween
20 buffer and the specific reactivity was detected by chemi-
luminescence technique (Amersham) according to the
manufacturer’s instructions (Cell Signaling Technology).
Statistical analysis
PRC2 proteins and categories of different prognostic fac-
tors (gender, age, WBC count, relapse and prednisone
response) was analyzed by chi-square test.
Then, the patients’ dichotomous variables were
assessed according to their influence on relapse and
disease-free survival (DFS). DFS estimated at 5 years by
the Kaplan‐Meier analysis, was assessed using a log-rank
test. In the DFS analysis, relapse and death in remission
as a result of any cause were considered treatment fail-
ures. DFS was calculated for all patients that obtained
complete remission from the date of remission to re-
lapse. Results were expressed as probability (percent)
and 95 % confidence intervals (CI). The hazard ratio
(HR; with a 95 % CI) for PRC2 subunits was estimated
by the Cox regression analysis and categorized according
to relapse risk prediction with the common prognostic
factors. Data are given as mean ± SD. Differences were




Twenty patients (15 males and 5 females) were included
in this study. The median age of the patients at diagnosis
was 120 months. The whole group was enrolled in
AIEOP-BFM treatment protocols. Morphologically the
patients were stratified as L1 (4 cases) and L2 (16 cases),
according to French American British (FAB) classifica-
tion. At presentation, fourteen patients (77.8 %) had
white blood cells (WBC) higher than 20,000/mmc and
six (22.2 %) a lower count (Table 2). They were sub-
divided into three risk categories, according to their
prognostic parameters: standard risk (SR) if a white cell
count below 20,000/mmc, DNA index between 1.16 and
1.60, good response to prednisone treatment (blasts re-
duction in peripheral blood <1,000/mmc after 7 days
treatment with steroids), no translocation t (9;22) or t
(4;11), complete remission at the conclusion of induc-
tion therapy; high risk (HR) if negative response to pred-
nisone, evidence of translocation t(9;22) o t(4;11), not in
remission at the conclusion of induction therapy, and
Intermediate risk (IR) whose characteristics did not fall
into either of the previous two categories. According to
these features our patients were sub-classified as SR for
3 patients (15 %) and HR for 17 patients (85 %). Clinical,
pathological data and evolution of the 20 patients are
listed in Table 2. Overall, with a median follow-up of
31 months (95 % C.I 14.2–59.9), 11 patients (55 %) were
alive and in continuous complete remission. Nine pa-
tients (45 %) relapsed.
Table 2 Clinical characteristics and pathologic data of 20
patients enrolled in the study



















WBC White Blood Cell, PDN Prednisone, GR Good Responders, PR
Poor Responders
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PRC2 expression in T-ALL primary patients
We have studied PRC2 expression and analysed the ex-
pression of mRNA in primary samples at diagnosis and on
Jurkat cell line, by real time PCR based on RNA sample
availability. EZH2 was markedly expressed like SUZ12 and
EED (Fig. 1a); in details, the analysis showed from 0.5 to 7-
fold higher expression of EZH2 compared to the control
samples. We have also quantified protein expression by
western blotting through the evaluation of the densities of
the corresponding bands after laser scanning and represen-
tation as percentage. We have calculated the cut off values
and we considered “low” expression values less than or
equal to 60 % and “high” expression higher than 60. EZH2
was expressed in 16/20 (75 %) samples at different extents:
4 samples (25 %) showed low expression levels, whereas 12
samples (75 %) had high levels. SUZ12 was expressed in 12
(60 %) samples; 5 (41.6 %) showed low levels and 7
(58.3 %) high expression. EED was expressed in all sam-
ples; 8 (40 %) had low expression and 12 (60 %) high
expression (Fig. 1b-c). Moreover, Jurkat cell line
expressed EZH2 and EED proteins only. When we
compared EZH2, SUZ12 and EED expressions with
A C
B
Fig. 1 EZH2 Expression (a) EZH2 expression evaluated through real time PCR in sample control (CTRL), Jurkat and T-ALL samples. PRC2 expression
evaluated through immunoblotting (b) in T-ALL samples enrolled in the study and (c) representation of the densities of the bands corresponding
to EZH2, SUZ12 and EED expressed as percentage of expression after laser scanning
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clinical and biological characteristics of patients, we
did not found any significant correlation (p > 0.05,
data not shown).
EZH2, SUZ12 and EED expression and correlation with
clinical outcome
Estimated 5-year DFS by the Kaplan‐Meier analysis
shows that T-ALL expressing EZH2 had a lower prob-
ability of DFS compared to T-ALL negative cases for
EZH2 (23 % vs 100 %) (log-rank test, p = 0.02, Fig. 2a).
These data were confirmed when negative and low ex-
pression samples were grouped vs high expression (22 %
vs 100 %) (log-rank test, p = 0.02, Fig. 2b). Moreover,
Kaplan‐Meier analysis shows that patients with high
EED expression had a lower probability of DFS vs low
expression patients (14 % vs 86 %) (log-rank test, p =
0.009, Fig. 2c). No significant differences in DFS rate
were found between patients stratified according to
SUZ12 expression (43 % vs 57 %) (log-rank test, p >0.05,
Fig. 2d). The Cox model, containing gender, age, initial
WBC count, PDN response, FAB phenotype and EZH2
expression suggests that EZH2 is not an independent
prognostic factor (p > 0.05).
DZNep and Daunoblastine effects on Jurkat proliferation
Jurkat cell line is frequently used for delineating the
mechanism of differential susceptibility of neoplasm for
chemotherapy or radiation, which also emphasizes the
significance of the line as a model for studies on T-acute
lymphoblastic leukemia. DZNep and Daunoblastine re-
duced Jurkat number in a dose-dependent manner after
48 and 72 h from the beginning of incubation. DZNep
induced 50 % growth inhibition (IC50) at 48 and 72 h
with a concentration of 12 μM/ml, respectively, while
Daunoblastine induced a less pronounced growth inhib-
ition reaching the IC50 after 72 h at a concentration of
12 ng/ml. Moreover, only Daunoblastine was able to in-
duce a time-dependent reduction of cell growth while
DZNep reached a plateau after 48 h. (Fig. 3a-b)
Fig. 2 Kaplan–Meier analysis. Disease-free survival (DFS) and EZH2 expression (a, b ), EED expression (c) and SUZ12 expression (d)
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DZNep synergizes with Daunoblastine in Jurkat cell
growth inhibition
We have evaluated the growth inhibition induced by
DZNep in combination with Daunoblastine using data
elaborated with the dedicated software Calcusyn (by
Chou and Talalay, see also Materials and Methods sec-
tion). The experimental CI50s (combination index calcu-
lated for 50 % cell survival by isobologram analysis)
values reveal that the DZNep/Daunoblastine combin-
ation was synergistic when both agents were used at
(25:50 = Daunoblastine:DZNep) concentrations, in fact
the CI50s were 0.6 at 48 h and 0.65 at 72 h (Fig. 4a-b).
These results suggested that the activity of a combin-
ation based on the use of an EZH2 inhibitor (DZNep)
with a conventional chemotherapy agent (already used
in high risk ALL at the clinical setting) could be useful
in EZH2 over-expressing cells.
Cell cycle analysis after DZNep in combination with
Daunoblastine treatment
We determined the effects of DZNep or Daunoblastine
alone and DZNep/Daunoblastine treatment on Jurkat cell
cycle. As demonstrated in Fig. 5, at 48 h, DZNep treatment
increased the percentage of cells in S-phase from 25 to
60 %; DZNep used in combination with Daunoblastine de-
termined an additional increase of cells in S-Phase reach-
ing an about 70 %. At the same time, cells in G0/1 phase
decreased in a statistically significant manner (p < 0.001).
These results on cell-cycle distribution were confirmed at
72 h (p <0.001).
Fig. 3 DZNep and Daunoblastine in Jurkat cell growth. Dose-dependent inhibitory effect of Daunoblastine (a) and DZNep (b) on Jurkat cells treated with
different concentrations of DZNep or Daunoblastine at 48 and 72 h as described in Materials and Methods section. Percentage of cell growth induced
by different concentrations of agents was evaluated with MTT assay. Each point is the mean of three different evaluations performed in at least three
different experiments
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The synergistic effect of the DZNep/Daunoblastine
combination on growth inhibition is paralleled by the
apoptosis induction
After the treatment with DZNep and Daunoblastine, used
at IC50 concentrations as described above, we have evalu-
ated the induction of apoptosis on Jurkat by FACS analysis,
after staining with Annexin V-FITC and PI, as described
above. As shown in Fig. 6, we found an increase of apop-
totic cells treated with the two agents in combination,
compared to untreated cells or cells treated with the single
agents. In details, we found that the treatment with
DZNep for 48 h induced apoptosis in about 41.5 % (34.6 %
late and 6.9 % early) of Jurkat cell population, while the
treatment with Daunoblastine for 48 h induced apoptosis
in about 27.9 % (20.5 % late and 7.4 % early) (p < 0.0001)
of Jurkat population compared to 9.6 % of untreated cells.
On the other hand, when the cells were treated with
DZNep +Daunoblastine, apoptosis was recorded in about
45.5 % (34.3 % late and 11.2 % early) of Jurkat cell popula-
tion (p < 0.0001) (Fig. 6a).
It is noteworthy that DZNep treatment for 72 h in-
duced apoptosis in 63 % (53.1 % late and 9.9 % early),
Daunoblastine treatment in 32.1 % (26.1 % late and 6 %
early) and the combination in about 67 % (52.2 % late
and 15 % early) of Jurkat (p < 0.0001) (Fig. 6b). On the
basis of these findings, it can be assumed that the com-
bination was able to induce strong apoptosis that was
paralleled by the synergism on cell growth inhibition.
On the basis of these results, we have evaluated the ef-
fect of treatment with the agents alone or in combination
on the mechanisms of apoptotic occurrence. The combin-
ation determined an increase of caspase-3 and caspase-9
cleaved isoforms, as a marker of their activity. Supporting
the hypothesis of the activation in the apoptotic pathway,
we observed a complete depletion of Bcl-2 in Jurkat cells
treated with DZNep alone and in combination with Dau-
noblastine (Fig. 6c).
DZNep treatment: EZH2 modulation in Jurkat
We assessed EZH2 expression levels after DZNep and
DZNep/Daunoblastine treatment in order to investigate
upon the effects of the inhibitor in Jurkat cells. Quanti-
tative RT-PCR analysis of EZH2 showed an about 50 %
decreased expression in cells treated with the single
agents or the combinations at 72 h (Fig. 7a). Moreover,
we found an almost complete EZH2 protein depletion
A B
Fig. 4 DZNep with Daunoblastine in Jurkat cell growth inhibition. DZNep and Daunoblastine have a synergistic effect on Jurkat cell growth inhibition. We
have evaluated the growth inhibition induced by different concentrations of DZNep and Daunoblastine at 48 (a) and 72 h (b). We have performed these
experiments with MTT assay and the resulting data were elaborated with the dedicated software Calcusyn as described in “Materials and Methods” section.
In the figure, it is shown the isobologram analysis of the effects on growth inhibition of DZNep and Daunoblastine combinations, used (25:50)
concentrations. CI, combination index. Each point is the mean of at least four different replicate experiments
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both in cells treated with DZNep and DZNep and Dau-
noblastine in combination at 48 h while an about 50 %
EZH2 protein reduction was recorded in Daunoblastine-
treated cells (Fig. 7b).
Effects of DZNep/Daunoblasatine combination on survival
signal transduction
Finally, we studied the effects of the agents on both the
expression and activity of two key molecules involved in
the regulation of both cell proliferation and survival pro-
cesses. In details, to elucidate the signaling pathways
underlying the effects of DZNep on Jurkat cells, MAPK
(Erk-1/phosphorylated Erk-1/2) and AKT were examined.
In Jurkat cells, DZNep alone did not induce modulation
in Erk-1/2 expression and activity while Daunoblastine
caused an about 50 % decrease of Erk-1/2 expression and
phosphorylation if compared to untreated cells. The com-
bined treatment strengthened the reduction of both activ-
ity and expression of Erk-1/2 (Figure 8 a, b and e).
We have found that DZNep alone and in combination
did not induce significant changes in Akt expression.
Moreover, we have evaluated the effect of the single agents
and the combination on the modulation of Akt activity. In
details, we found that neither the single agents nor the
combination induced any significant changes on the activ-
ity of the survival Akt enzyme (Figure 8 c and e).
Discussion
Stringent assessment of the relapse hazard in individ-
ual patients with ALL is an integral part of the mod-
ern approach to ALL therapy. Recently, the response
to treatment is the most important prognostic factor
in ALL. Indeed, many other variables have emerged
as useful prognostic indicators. Moreover, the prog-
nostic impact of age and, to a lesser extent, leukocyte
count can be explained partly by their association
with specific genetic abnormalities. It should be em-
phasized that primary genetic features do not entirely
account for treatment outcome. For instance, up to
A B
Fig. 5 Effect of the DZNep and Daunoblastine treatment on cell cycle. We have evaluated the distribution of Jurkat cells at 48 h (a) and 72 h (b) in the
different phases of the cell cycle, after the treatments with DZNep and/or Daunoblastine as previously described. This experiment was performed by
FACS analysis after PI staining as described in Materials and Methods section
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20 % of patients with favorable features as hyperdi-
ploidy > 50 chromosomes or TEL-AML1 fusion con-
tinue to suffer recurrences for their leukemia [21].
Moreover, inactivation of the p53 gene through muta-
tions or overexpression of HDM2 whose product can
bind to p53 and induce its degradation, is associated
with a poor prognosis in children with ALL. The in-
dependent prognostic importance of a patient’s gross
early response to therapy has been recognized since
the early 1980s. At the present, it is very important
the measurement of minimal residual disease (MRD)
by flow-cytometric detection of aberrant immunophe-
notypes or analysis by polymerase chain reaction
(PCR) to afford a level of sensitivity and specificity
that cannot be attained by traditional morphological
assessment of treatment response [22].
In the last few decades, the survival in pediatric T-ALL
patients has significantly improved, yet one patient in
every four still encounters relapse and in most cases
early. To date, few biomarkers have proved to be reliable
in predicting T-ALL patient prognosis. The introduction
of new factors that can lead to a more accurate patient
risk stratification and the related treatment approach is
expected to improve T-ALL outcome [22].
Recently, early T-cell precursor (ETP) ALL was identi-
fied as a T-ALL subgroup with a very poor outcome [23].
Moreover Zhang J et al. showed that ETP-ALL cases




Fig. 6 (a). The effect of DZNep/Daunoblastine combination on apoptosis. FACS analysis after double labelling of Jurkat cells with PI and Annexin V.
Jurkat were treated with DZNep and Daunoblastine alone and in combination, compared to the control. The experiments were performed at least
three times and the results were always similar. Insets, % of positive cells. UL = Upper Left (necrosis); UR = Upper Right (late apoptosis); LL = Lower Left
(viable); LR = Lower Right (early apoptosis). Untreated cells, CTR; Dauno added for 48 h, DZNep 48 h; DZNep +Dauno added for 48 h. (a). The figure is
representative of three different experiments that always gave similar results. The table shows the percentage of cells in the different quadrants. (b).
FACS analysis after double labelling Jurkat with PI and Annexin V. Jurkat were treated with DZNep and Daunoblastine alone and in combination,
compared to the control at 72 h. (c). Cells were then processed for the determination of the expression of caspase 3, caspase 9 and Bcl2 evaluated after
blotting with specific antibodies described in Materials and Methods section. The house-keeping protein beta-tubulin was used as loading control. CTR,
untreated; Dauno, DZNep and Dauno/DZNep treated cells as described before. Each point is representative of three different evaluations performed in
at least three different experiments. Scan of the bands associated with caspase 3, caspase 9 and Bcl2 expression in Jurkat cells, normalized with the
house-keeping protein, was performed with a dedicated software and the intensities of the bands were expressed as percentage protein expression (%,
mean of three different experiments). Bars, s.e.’s
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regulating cytokine receptor and RAS signaling, inacti-
vating lesions disrupting haematopoietic development,
and histone modifying genes (EZH2, EED, SUZ12,
SETD2 and EP300) [24].
EZH2 overexpression is implicated in tumorigenesis and
correlates to poor prognosis in several tumour types [25].
Moreover, EZH2 is considered one of the most appeal-
ing epigenetic targets for therapy in human cancer but ef-
ficiency of how it regulates its target genes depends on a
number of additional factors, which may differ from one
tumor cell line to another, even of the same tissue [26].
Here we have shown an expression of EZH2 and EED in
20 samples of T cells ALL and our findings suggest that
their over-expression gives a lower probability of DFS.
Therefore, EZH2 expression might be taken in account
for a more precise and reliable patient stratification in
order to improve treatment selection.
Epigenetic therapy in patients with hematological ma-
lignancies has produced interesting responses, but few
long-term survivors [3]. Daunoblastine has been used as
an anti-leukemic agent for decades, its success is often
dependent on combination with other drugs. An inter-
esting epigenetic agent that has the potential to increase
anti-leukemic action of Daunoblastine could be DZNep.
DZNep was first studied to enlarge the antiviral drugs
arsenal and was further shown to induce cancer cell
death [27]. DZNep became a promising anti-tumor drug
with a significant efficacy on various cell types and no
evident toxicity in vivo [28]. Studies by Momparler et al.
revealed that sequential treatment of 5-AZA-CdR
followed by DZNep showed a synergistic interaction
with respect to its antileukemic activity as shown by a
loss of clonogenicity for both human myeloid and mur-
ine lymphoid leukemic cell lines [3]. In this study, we
demonstrated for the first time that DZNep and Dauno-
blastine used in combination at 25:50 concentrations,
were synergistic at the Calcusyn elaboration. This sug-
gested the opportunity to use EZH2 inhibitor and Dauno-
blastine combination in the treatment of paediatric T-ALL.
Indeed, we observed that the synergistic combinations
produced also a strong pro-apoptotic effect on Jurkat cell
line. In details, DZNep alone and in combination with
A
B
Fig. 7 EZH2 modulation in Jurkat. (a) EZH2 expression evaluated through real time PCR in Jurkat at 48 and 72 h after treatment with Dauno, DZNep
and Dauno+DZNep. (b) EZH2 expression evaluated through immunoblotting in Jurkat cell line treated at 48 h with Dauno, DZNep and Dauno +
DZNep. The experiments were repeated three times and the values are the mean ± SD of the three independent experiments
D’Angelo et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:83 Page 11 of 13
Daunoblastine induced 63 % and 67 % of apoptosis at
72 h, respectively. It was shown that DZNep could inhibit
the Jurkat cell proliferation activating probably check-
points which cause cell cycle arrest at S phase, resulting in
acceleration of apoptosis. In fact, in natural killer/T-cell
lymphoma, EZH2 upregulated via Myc-mediated mRNA
inhibition, directly activates cyclin D transcription and
promotes cell proliferation independently from methyl-
transferase activity [29]. Despite the main function of
EZH2 is gene silencing through the methylation of H3K27,
several studies have shown that EZH2 acts as trascriptional
activator in various types of cancer independently from
H3K27me. For example in natural killer/T-cell lymphoma,
EZH2 upregulation directly activates cyclin D transcrip-
tion via Myc-mediated mRNA inhibition and promotes
cell proliferation independently from methyltransferase
activity [29]. In the same way, EZH2 upregulation found
in Jurkat cell line likely activates cyclin D transcription
explaining the effect of DZNep obtained in our experi-
mental system. Our results revealed that the treatment
with both agents changed the expression and activity of
many important proteins including caspase-3, 9, Bcl-2,
Erk and EZH2. Among these proteins, the down-
regulation of Bcl-2 and up-regulation of cleaved Caspase-
3 and Caspase-9 are on-line with apoptosis occurrence
observed in cells treated with the combination. At the
same time, the combination was also able to modulate
Erk-mediated proliferation pathway. In details, we ob-
served that Erk phosphorylation was significantly inhibited
by the combined treatment. This observation raises the
possibility that treatment regimen with DZNep +Dauno-
blastine might be used to treat T-ALL cell, particularly the
subgroup at worse prognosis.
Conclusion
Gene regulation by PRC2 complex is critical in tumori-
genesis. Gene repression resulting from EZH2 activity is a
key component of the epigenetic machinery with effects
on both DNA and histone methylation. Our data on






Fig. 8 DZNep/Daunoblasatine combination on survival signal transduction. The cells were processed for the determination of the expression (a) and
phosphorylation (b) of erk-1 and 2 evaluated after blotting with an anti-MAPK- and an anti-pMAPK-specific Mab, respectively, as described in ‘Materials
and methods’. In the same experimental conditions, the activity (c) of Akt was also analysed with a Western blotting and an in-gel kinase
assay, respectively, as described in ‘Materials and methods’. (d) Expression of the house-keeping protein beta-tubulin, used as loading control. The
experiments were performed at least three different times and the results were always similar. CTR, untreated; Dauno; DZNep; Dauno/DZNep. (e) Scan of
the bands associated with Erk 1/2 and Akt activity was performed with a dedicated software and the intensities of the bands were expressed as arbitrary
units (%, mean of three different experiments). Bars, s.e.’s
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EZH2 in the regulation of biological functions in T-ALL.
Our study shows, for the first time, that reduction of
EZH2 levels potentiates growth inhibition and apoptosis
caused by Daunoblastine in Jurkat cell line. Pharmaco-
logical targeting of EZH2 might represent a potential feas-
ible approach to be used as adjuvant treatment for making
conventional therapy more effective in pediatric T-ALL.
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